bluebird bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
02 Agosto 2024 - 3:05PM
Business Wire
bluebird bio, Inc. (Nasdaq: BLUE) today announced that
the Compensation Committee of the Company’s Board of Directors
approved an inducement grant of stock options to purchase a total
of 38,200 shares of common stock to its controller and vice
president of accounting, Joe Ewer, with a grant date of August 1,
2024.
The stock options approved under the Inducement Plan have an
exercise price per share equal to $1.08, the fair market value of
the Company’s common stock on the grant date. The stock options
vest over four years, with 25% vesting on the one-year anniversary
of the grant date and 1/36 of the remaining shares vesting monthly
thereafter, subject to Mr. Ewer’s continued service with the
Company on each such date. The stock options have a 10-year term
and are subject to the terms and conditions of the stock option
agreement.
The Company granted the stock options as inducement materials to
Joe Ewer entering into employment with bluebird bio, Inc. in
accordance with NASDAQ Listing Rule 5635(c)(4).
About bluebird bio, Inc.
bluebird bio is pursuing curative gene therapies to give
patients and their families more bluebird days.
Founded in 2010, bluebird has been setting the standard for gene
therapy for more than a decade—first as a scientific pioneer and
now as a commercial leader. bluebird has an unrivaled track record
in bringing the promise of gene therapy out of clinical studies and
into the real-world setting, having secured FDA approvals for three
therapies in under two years. Today, we are proving and scaling the
commercial model for gene therapy and delivering innovative
solutions for access to patients, providers, and payers.
With a dedicated focus on severe genetic diseases, bluebird has
the largest and deepest ex-vivo gene therapy data set in the field,
with industry-leading programs for sickle cell disease,
β-thalassemia and cerebral adrenoleukodystrophy. We custom design
each of our therapies to address the underlying cause of disease
and have developed in-depth and effective analytical methods to
understand the safety of our lentiviral vector technologies and
drive the field of gene therapy forward.
bluebird continues to forge new paths as a standalone commercial
gene therapy company, combining our real-world experience with a
deep commitment to patient communities and a people-centric culture
that attracts and grows a diverse flock of dedicated birds.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240802449243/en/
Investors: Courtney O’Leary, 978-621-7347
coleary@bluebirdbio.com
Media: Jess Rowlands, 857-299-6103
jess.rowlands@bluebirdbio.com
bluebird bio (NASDAQ:BLUE)
Gráfica de Acción Histórica
De Sep 2024 a Oct 2024
bluebird bio (NASDAQ:BLUE)
Gráfica de Acción Histórica
De Oct 2023 a Oct 2024